Skip to main content
SpringerLink
Log in

Antioxidants and Restenosis after Percutaneous Coronary Intervention: Human Studies

  • Chapter
Antioxidants and Cardiovascular Disease

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 258))

  • 948 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith SC, Jr., Dove JT, Jacobs, AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103:3019–41.

    PubMed  Google Scholar 

  2. Landau C, Lange RA, Hillis, LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994;330:981–93.

    Article  PubMed  CAS  Google Scholar 

  3. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217–25.

    Article  Google Scholar 

  4. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 299 patients. J Am Coll Cardiol 1988;12:616–23.

    Google Scholar 

  5. Bourassa MG, Lespérance J, Eastwood C, et al. Physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1991;18:368–76.

    PubMed  CAS  Google Scholar 

  6. Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001;38:645–52.

    Article  PubMed  CAS  Google Scholar 

  7. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138:777–86.

    PubMed  Google Scholar 

  8. Morice M, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773–80.

    Article  PubMed  CAS  Google Scholar 

  9. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stent versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315–23.

    Article  PubMed  CAS  Google Scholar 

  10. Grube E, Silber S, Hauptmann KE, et al. TAXUS-1: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38–42.

    Article  PubMed  CAS  Google Scholar 

  11. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221–31.

    Article  PubMed  CAS  Google Scholar 

  12. Hernandez RA, Macaya C, Iniguez A, et al. Midterm outcome of patients with asymptomatic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1992;19:1402–9.

    PubMed  CAS  Google Scholar 

  13. Bourassa MG. Silent myocardial ischemia after coronary angioplasty: distinguishing the shadow from the substance. J Am Coll Cardiol 1992;19:1410–1.

    Article  PubMed  CAS  Google Scholar 

  14. Sheppard R, Schechter D, Azoulay A, Witt H, Garzon P, Eisenberg MJ. Results of a routine exercise treadmill testing strategy early after percutaneous transluminal coronary angioplasty. Can J Cardiol 2001;17:407–14.

    PubMed  CAS  Google Scholar 

  15. Lespérance J, Bourassa MG, Schwartz L, et al. Definition and measurement of restenosis after successful coronary angioplasty: implications for clinical trials. Am Heart J 1993;125:1394–1408.

    Article  PubMed  Google Scholar 

  16. Lespérance J, Bilodeau L, Reiber JHC, Koning G, Hudon G, Bourassa MG. Issues in the performance of quantitative coronary angiography in clinical research trials. In: What is New in Cardiovascular Imaging? J.H.C. Reiber and E.E. van der Wall (eds.): Kluwer Academic Publishers, The Netherlands 1998:31–46.

    Google Scholar 

  17. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 1995;25:516–20.

    Article  PubMed  CAS  Google Scholar 

  18. Strauss BH, Chisholm RJ, Keely FW, Gotlieb AI, Logan RA, Armstrong PW. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res 1994;75:650–8.

    PubMed  CAS  Google Scholar 

  19. Coté G, Tardif JC, Lespérance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999;99:30–5.

    PubMed  Google Scholar 

  20. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35–43.

    PubMed  CAS  Google Scholar 

  21. Langille BL, O’Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986;231:405–7.

    PubMed  CAS  Google Scholar 

  22. Serruys PW, de Jaegere P, Kiemeneij F, et al. for the Benestent Study Group. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489–95.

    Article  PubMed  CAS  Google Scholar 

  23. Hoffman R, Mintz GS, Dusaillant GR, et al. Patterns and mechanisms of in-stent restenosis. Circulation 1996;94:1247–54.

    Google Scholar 

  24. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997;95:1366–9.

    PubMed  CAS  Google Scholar 

  25. Rodès J, Tardif JC, Lespérance J, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998;97:429–36.

    PubMed  Google Scholar 

  26. Bertrand O, Mongrain R, Tardif JC, Bourassa MG. Prevention of restenosis using ionizing radiation. Rev Med Liege 1998;53:419–24.

    PubMed  CAS  Google Scholar 

  27. Teirstein P, Massulo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336;1697–703.

    Article  PubMed  CAS  Google Scholar 

  28. Meerkin D, Tardif JC, Crocker IR, et al. Effects of intracoronary beta-radiation therapy after coronary angioplasty: an intravascular ultrasound study. Circulation 1999;99:1660–5.

    PubMed  CAS  Google Scholar 

  29. Tardif JC, Coté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365–72.

    Article  PubMed  CAS  Google Scholar 

  30. Tardif JC, Coté G, Lespérance J, et al. Impact of residual plaque burden after balloon angioplasty in the multivitamins and probucol (MVP) trial. Circulation 1998;98:I-89 (abstract).

    Google Scholar 

  31. Lee YJ, Yamaguchi H, Daida H, et al. Pharmacological interventions to modify restenosis. Circulation 1991;84:II-299 (abstract).

    Google Scholar 

  32. Setsuda M, Inden M, Hiraoka N, et al. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clinical Therapeutics 1993;15:374–81.

    PubMed  CAS  Google Scholar 

  33. Watanabe K, Sekyia M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;13:23–9.

    Article  Google Scholar 

  34. Lee YJ, Daida H, Yokoi H, et al. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J. 1996;37:327–32.

    PubMed  CAS  Google Scholar 

  35. Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty. The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997;30:855–62.

    Article  PubMed  CAS  Google Scholar 

  36. Yokoi H, Daida H, Yamaguchi H, Kuwabara Y, for the PART Group. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty in small coronary arteries: a subgroup analysis of the Probucol Angioplasty Restenosis Trial (PART). J Am Coll Cardiol 1997;29:418A (abstract).

    Google Scholar 

  37. Roberts MJD, Young IS, Trouton TG, et al. Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 1990;336:143–5.

    Article  PubMed  CAS  Google Scholar 

  38. Iuliano L, Pratico D, Greco C, et al. Angioplasty increases coronary sinus F2-isoprostane formation: evidence for an in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001;37:76–80.

    Article  PubMed  CAS  Google Scholar 

  39. Kugiyama K, Kerns SA, Morissett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160–2.

    Article  PubMed  CAS  Google Scholar 

  40. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915–24.

    Article  PubMed  CAS  Google Scholar 

  41. Rajapopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572–9.

    Google Scholar 

  42. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994;75:539–45.

    PubMed  CAS  Google Scholar 

  43. Reiser K, McCormick RJ, Rucker RB. Enzymatic and non-enzymatic cross-linking of collagen and elastin. FASEB J 1992;6:2439–49.

    PubMed  CAS  Google Scholar 

  44. O’Keefe JH, Jr., Stone GW, McCallister BD, et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649–52.

    Article  PubMed  CAS  Google Scholar 

  45. Reaven PD, Parthasarathy S, Beltz WF, Witzum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992;12:318–24.

    PubMed  CAS  Google Scholar 

  46. Edelman ER. Vessel size, antioxidants, and restenosis. Never too small, not too little, but often too late. Circulation 1998;97:416–20.

    PubMed  CAS  Google Scholar 

  47. Bowry VW, Ingold KU, Stacker R. Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant. Biochem J 1992;288:341–4.

    PubMed  CAS  Google Scholar 

  48. Tardif JC, Grégoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552–8.

    Article  PubMed  CAS  Google Scholar 

  49. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488–93.

    Article  PubMed  CAS  Google Scholar 

  50. McLean LR, Thomas CE, Weintraub B, et al. Modulation of the physical state of cellular cholesteryl esters by probucol. J Biol Chem 1992;267:12291–8.

    PubMed  CAS  Google Scholar 

  51. Tardif JC. The future of intravascular ultrasound in the detection and management of coronary artery disease. Can J Cardiol 2000;16(Suppl.D): 12D–15D.

    PubMed  Google Scholar 

  52. Nunes GL, Robinson K, Kalynych A, et al. Vitamins C and E inhibit 02-production in the pig coronary artery. Circulation 1997;96:3593–601.

    PubMed  CAS  Google Scholar 

  53. Tardif JC, Grégoire J, L’Allier PL. Prevention of restenosis with antioxidants. Mechanisms and implications. Am J Cardiovasc Drugs 2002;2:323–34.

    Article  PubMed  CAS  Google Scholar 

  54. Buckley MMT, Goa KL, Price AH, et al. Probucol, a reappraisal of the pharmacological properties and therapeutic use in hypercholesterolemia. Drugs 1989;37:761–800

    PubMed  CAS  Google Scholar 

  55. Parthasarathy S, Young SG, Witzum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986;77:641–4.

    PubMed  CAS  Google Scholar 

  56. Chisholm GM III, Morel DW. Lipoprotein oxidation and cytotoxicity effect of probucol on streptomycin-treated rats. Am J Cardiol 1988;62:20B–26B.

    Article  Google Scholar 

  57. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. Is the extent of atherosclerosis related to the resistance of LDL to oxidation? J Clin Invest 1994;94:155–64.

    PubMed  CAS  Google Scholar 

  58. Steinberg D, Parthasarathy S, Carew TE. In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am J Cardiol 1988;62:6B–12B.

    Article  PubMed  CAS  Google Scholar 

  59. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725–9.

    Article  PubMed  CAS  Google Scholar 

  60. Ku G, Doherty NS, Wolos JA, Jackson RL. Inhibition by probucol of interleukin-1 secretion and its implication in atherosclerosis. Am J Cardiol 1988;62:77B–81B.

    Article  PubMed  CAS  Google Scholar 

  61. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647–50.

    PubMed  CAS  Google Scholar 

  62. Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrythmic events and QT prolongation: importance of gender. Am Heart J 1996; 131:1184–91.

    Article  PubMed  CAS  Google Scholar 

  63. Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (torsades de pointe) associated with the use of probucol. N Engl J Med 1992;326:1435–6.

    PubMed  CAS  Google Scholar 

  64. Kajinami K, Takeoshi N, Mabuchi H. Propranolol for probucol-induced QT prolongation with polymorphic ventricular tachycardia. Lancet 1993;341:124–5.

    Article  PubMed  CAS  Google Scholar 

  65. Matsuhashi H, Onodera S, Kawamura Y, et al. Probucol-induced QT prolongation and torsades de pointe. Jpn J Med 1989;28:612–5.

    PubMed  CAS  Google Scholar 

  66. Naruszewicz M, Carew TE, Pittman RC, et al. A novel mechanism by which probucol lowers LDL levels demonstrated in the LDL-receptor deficient rabbit. J Lipid Res 1984;25:1206–13.

    PubMed  CAS  Google Scholar 

  67. Schwartz CJ. The probucol experience: a review of the past and a look at the future. Am J Cardiol 1988;62:1B–5B.

    Article  PubMed  CAS  Google Scholar 

  68. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875–83.

    Article  PubMed  CAS  Google Scholar 

  69. Johansson J, Olsson AG, Bergstrand L, et al. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) report. Arterioscler Thromb Vasc Biol 1995;15:1049–56.

    PubMed  CAS  Google Scholar 

  70. Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2003;12:2545–8.

    Article  Google Scholar 

  71. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999;85:753–66.

    PubMed  CAS  Google Scholar 

  72. Marui N, Offerman MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866–74.

    PubMed  CAS  Google Scholar 

  73. Wasserman MA, Sundell CL, Kunsch C, et al. Chemestry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol 2003;91(suppl.):34A–40A.

    Article  PubMed  CAS  Google Scholar 

  74. Gordon DG, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989;321:1311–6.

    Article  PubMed  CAS  Google Scholar 

  75. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995;96:2071–4.

    PubMed  CAS  Google Scholar 

  76. Busch SJ, Barnhart RL, Martin GA, et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994;269:16376–82.

    PubMed  CAS  Google Scholar 

  77. de Backer G, de Backer D, Kornitzer M. Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis 1998;137(Suppl.):S1–S6.

    PubMed  Google Scholar 

  78. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13–27.

    Google Scholar 

  79. von Eckardstein A, Nofer JR, Assmann G. Acceleration of reverse cholesterol transport. Curr Opin Cardiol 2000; 15:348–54.

    Google Scholar 

  80. Kuzuya M, Naito M, Funaki C, Hayashi T, Asai K, Kuzuya F. Probucol prevents oxidative injury in endothelial cells. J Lipid Res 1991;32:197–204.

    PubMed  CAS  Google Scholar 

  81. Yamamoto A, Hara H, Takaichi S, et al. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol 1988;62:31B–36B.

    Article  PubMed  CAS  Google Scholar 

  82. Chang MY, Sasahara M, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. Cellular composition and proliferation. Arterioscler Thromb Vasc Biol 1995;15:1631–40.

    PubMed  CAS  Google Scholar 

  83. Weintraub Ws, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331–7.

    Article  PubMed  CAS  Google Scholar 

  84. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthetize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994;75:181–9.

    PubMed  CAS  Google Scholar 

  85. Tardif JC, Pandian NG. Intravascular ultrasound imaging in peripheral arterial and coronary artery disease. Curr Opin Cardiol 1994;9:627–33.

    PubMed  CAS  Google Scholar 

  86. Jialal I, Grundy SM. Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res 1992;33:899–906.

    Google Scholar 

  87. Burton GW, Ingold KU. Vitamin E as an in vitro and in vivo antioxidant. Ann N Y Acad Soi 1989;570:7–22.

    CAS  Google Scholar 

  88. Brin MF, Fahn S, Loftus S, McMahon D, Flaster, E. Relationship between dose of vitamin E administered and blood level. Ann N Y Acad Sci 1989;570:421–4.

    Google Scholar 

  89. Cavarocchi NC, England MD, O’Brien JF, et al. Superoxide generation during cardiopulmonary bypass: is there a role for vitamin E? J Surg Res 1986;40:519–27.

    Article  PubMed  CAS  Google Scholar 

  90. Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. J Lipid Res 1992;33:385–97.

    PubMed  CAS  Google Scholar 

  91. Shaish A, Daugherty A, O’Sullivan F, Schonfeld G, Heinecke JW. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest 1995;96:2075–82.

    Article  PubMed  CAS  Google Scholar 

  92. Keaney JF Jr., Gaziano JM, Xu A, et al. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci USA 1993;90:11880–4.

    Article  PubMed  CAS  Google Scholar 

  93. Nunes GI, Sgoutas DS, Redden RA, et al. Combination of vitamin C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol 1995;15:156–65.

    PubMed  CAS  Google Scholar 

  94. Keaney JF Jr., Gaziano JM, Xu A, et al. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994;93:844–51.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Montreal Heart Institute, Montreal, Quebec, Canada

    Martial G. Bourassa & Jean-Claude Tardif

Authors
  1. Martial G. Bourassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Claude Tardif
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Montreal Heart Institute Research Center and Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

    Martial G. Bourassa  & Jean-Claude Tardif  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Bourassa, M.G., Tardif, JC. (2006). Antioxidants and Restenosis after Percutaneous Coronary Intervention: Human Studies. In: Bourassa, M.G., Tardif, JC. (eds) Antioxidants and Cardiovascular Disease. Developments in Cardiovascular Medicine, vol 258. Springer, Boston, MA. https://doi.org/10.1007/0-387-29553-4_14

Download citation

  • DOI: https://doi.org/10.1007/0-387-29553-4_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-29552-7

  • Online ISBN: 978-0-387-29553-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation